Celldex Therapeutics, Inc.CLDX was a big mover last session, as the company saw its shares rise nearly 12% on the day. The share price appreciation came after the company presented mature survival data from a phase II study on Rintega at the annual meeting of the Society for Neuro-Oncology. The news led to far more shares changing hands than in a normal session, breaking the recent trend for the company as the stock is now in now trading above the volatile price range of $12.06 to $15.46 over the past one-month time frame.
The stock witnessed five upward estimate revisions in the past 30 days. The Zacks Consensus Estimate also moved up over the same time frame, suggesting that more solid trading could be ahead for Celldex Therapeutics. So make sure to keep an eye on this stock going forward to see if the latest jump can turn into more strength down the road.
Celldex Therapeutics carries a Zacks Rank #2 (Buy).
Another stock in the med-biomed/gene industry worth considering is Achillion Pharmaceuticals, Inc. ACHN , with a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report